Skip to content

Study · In silico · 2025

7 results

The cost-utility and budget impact analyses of Tirzepatide versus once-weekly Semaglutide as add-on therapy to metformin in patients with type 2 diabetes mellitus in China.

Wang S, Fan D, Yao Q, Sun X

Diabetes, obesity & metabolism2 Jul 2025Cited by 2 (Europe PMC)

PMID40600464 (opens in a new tab)DOI10.1111/dom.16580 (opens in a new tab)PepBankPUB-40600464
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01Computer modelIn silicoOther

    In a model of adults with type 2 diabetes on metformin in China, tirzepatide 5 mg yielded 0.05 more QALYs than semaglutide 1 mg.

    In plain wordsIn a computer model for type 2 diabetes in China, tirzepatide 5 mg gave slightly more healthy life years than semaglutide 1 mg.

    Peptide
    Tirzepatide
    Outcome
    IncreaseIncremental QALYs, tirzepatide 5 mg
    Study

    n: not reported in source

    UKPDS Outcomes Model Version 2.2 cost-utility model
    Comparator
    Semaglutide 1 mg
    Outcome group
    Healthcare costs and utilization · Metabolic and weight
    Studied dose
    5 mgAs given in this study.

    Measurements

    Incremental QALYs
    0.05 QALY
    tirzepatide 5 mg vs semaglutide 1 mg

    Source sentences

    Summary
    In the long-term treatment simulation, tirzepatide 5 and 10 mg yielded incremental QALYs of 0.05 and 0.09, in comparison with semaglutide 1 mg, respectively.
    2 context sentences
    Summary · context
    The demographic and clinical efficacy data were derived from the SURPASS-2 trial.
    Summary · context
    The cost-utility analysis was performed to estimate the cost-utility by UK Prospective Diabetes Study Outcomes Model Version 2.2 from the Chinese health care providers' perspective, incorporating costs and quality-adjusted life years (QALYs).
  2. 02Computer modelIn silicoOther

    In a model of adults with type 2 diabetes on metformin in China, tirzepatide 10 mg yielded 0.09 more QALYs than semaglutide 1 mg.

    In plain wordsIn a computer model for type 2 diabetes in China, tirzepatide 10 mg gave slightly more healthy life years than semaglutide 1 mg.

    Peptide
    Tirzepatide
    Outcome
    IncreaseIncremental QALYs, tirzepatide 10 mg
    Study

    n: not reported in source

    UKPDS Outcomes Model Version 2.2 cost-utility model
    Comparator
    Semaglutide 1 mg
    Outcome group
    Healthcare costs and utilization · Metabolic and weight
    Studied dose
    10 mgAs given in this study.

    Measurements

    Incremental QALYs
    0.09 QALY
    tirzepatide 10 mg vs semaglutide 1 mg

    Source sentences

    Summary
    In the long-term treatment simulation, tirzepatide 5 and 10 mg yielded incremental QALYs of 0.05 and 0.09, in comparison with semaglutide 1 mg, respectively.
    2 context sentences
    Summary · context
    The demographic and clinical efficacy data were derived from the SURPASS-2 trial.
    Summary · context
    The cost-utility analysis was performed to estimate the cost-utility by UK Prospective Diabetes Study Outcomes Model Version 2.2 from the Chinese health care providers' perspective, incorporating costs and quality-adjusted life years (QALYs).
  3. 03Computer modelIn silicoOther

    In a model of adults with type 2 diabetes on metformin in China, tirzepatide 5 mg had incremental costs of $23 563.42 versus semaglutide 1 mg.

    In plain wordsIn a computer model for type 2 diabetes in China, tirzepatide 5 mg cost more than semaglutide 1 mg.

    Peptide
    Tirzepatide
    Outcome
    IncreaseIncremental costs, tirzepatide 5 mg
    Study

    n: not reported in source

    UKPDS Outcomes Model Version 2.2 cost-utility model
    Comparator
    Semaglutide 1 mg
    Outcome group
    Healthcare costs and utilization · Metabolic and weight
    Studied dose
    5 mgAs given in this study.

    Source sentences

    Summary
    The associated incremental costs for these treatments were $23 563.42 and $47 583.74, respectively.
    2 context sentences
    Summary · context
    The demographic and clinical efficacy data were derived from the SURPASS-2 trial.
    Summary · context
    The cost-utility analysis was performed to estimate the cost-utility by UK Prospective Diabetes Study Outcomes Model Version 2.2 from the Chinese health care providers' perspective, incorporating costs and quality-adjusted life years (QALYs).
  4. 04Computer modelIn silicoOther

    In a model of adults with type 2 diabetes on metformin in China, tirzepatide 10 mg had incremental costs of $47 583.74 versus semaglutide 1 mg.

    In plain wordsIn a computer model for type 2 diabetes in China, tirzepatide 10 mg cost more than semaglutide 1 mg.

    Peptide
    Tirzepatide
    Outcome
    IncreaseIncremental costs, tirzepatide 10 mg
    Study

    n: not reported in source

    UKPDS Outcomes Model Version 2.2 cost-utility model
    Comparator
    Semaglutide 1 mg
    Outcome group
    Healthcare costs and utilization · Metabolic and weight
    Studied dose
    10 mgAs given in this study.

    Source sentences

    Summary
    The associated incremental costs for these treatments were $23 563.42 and $47 583.74, respectively.
    2 context sentences
    Summary · context
    The demographic and clinical efficacy data were derived from the SURPASS-2 trial.
    Summary · context
    The cost-utility analysis was performed to estimate the cost-utility by UK Prospective Diabetes Study Outcomes Model Version 2.2 from the Chinese health care providers' perspective, incorporating costs and quality-adjusted life years (QALYs).
  5. 05Computer modelIn silicoOther

    In a model of adults with type 2 diabetes on metformin in China, the incremental cost-utility ratio of tirzepatide 5 mg versus semaglutide 1 mg was $445 125.24/QALY, above the $29 599.90/QALY threshold.

    In plain wordsIn a computer model for type 2 diabetes in China, tirzepatide 5 mg cost far above the threshold per life year versus semaglutide 1 mg.

    Peptide
    Tirzepatide
    Outcome
    Not applicableIncremental cost-utility ratio, tirzepatide 5 mg
    Study

    n: not reported in source

    UKPDS Outcomes Model Version 2.2 cost-utility model
    Comparator
    Semaglutide 1 mg
    Outcome group
    Healthcare costs and utilization · Metabolic and weight
    Studied dose
    5 mgAs given in this study.

    Source sentences

    Summary
    Consequently, the incremental cost-utility ratios were calculated to be $445 125.24/QALY and $543 829.19/QALY, both of which exceeded the established threshold of $29 599.90/QALY.
    2 context sentences
    Summary · context
    The demographic and clinical efficacy data were derived from the SURPASS-2 trial.
    Summary · context
    The cost-utility analysis was performed to estimate the cost-utility by UK Prospective Diabetes Study Outcomes Model Version 2.2 from the Chinese health care providers' perspective, incorporating costs and quality-adjusted life years (QALYs).
  6. 06Computer modelIn silicoOther

    In a model of adults with type 2 diabetes on metformin in China, the incremental cost-utility ratio of tirzepatide 10 mg versus semaglutide 1 mg was $543 829.19/QALY, above the $29 599.90/QALY threshold.

    In plain wordsIn a computer model for type 2 diabetes in China, tirzepatide 10 mg cost far above the threshold per life year versus semaglutide 1 mg.

    Peptide
    Tirzepatide
    Outcome
    Not applicableIncremental cost-utility ratio, tirzepatide 10 mg
    Study

    n: not reported in source

    UKPDS Outcomes Model Version 2.2 cost-utility model
    Comparator
    Semaglutide 1 mg
    Outcome group
    Healthcare costs and utilization · Metabolic and weight
    Studied dose
    10 mgAs given in this study.

    Source sentences

    Summary
    Consequently, the incremental cost-utility ratios were calculated to be $445 125.24/QALY and $543 829.19/QALY, both of which exceeded the established threshold of $29 599.90/QALY.
    2 context sentences
    Summary · context
    The demographic and clinical efficacy data were derived from the SURPASS-2 trial.
    Summary · context
    The cost-utility analysis was performed to estimate the cost-utility by UK Prospective Diabetes Study Outcomes Model Version 2.2 from the Chinese health care providers' perspective, incorporating costs and quality-adjusted life years (QALYs).
  7. 07Computer modelIn silicoOther

    In a model of adults with type 2 diabetes on metformin in China, expanding tirzepatide use would add roughly $80 million to $490 million to the national health insurance budget over 5 years.

    In plain wordsIn a computer model for China, wider tirzepatide use would add a large cost to national health insurance over five years.

    Peptide
    Tirzepatide
    Outcome
    IncreaseBudget impact on national health insurance over 5 years
    Study

    n: not reported in source

    UKPDS Outcomes Model Version 2.2 cost-utility model
    Comparator
    Semaglutide 1 mg
    Outcome group
    Healthcare costs and utilization · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Additional budget burden
    80 to 490 million USD
    5-year simulation

    Source sentences

    Summary
    The budget impact analysis showed that such an expansion would incur an additional budgetary burden of approximately $80 million to $490 million for the NHIS over a simulated 5-year period.
    2 context sentences
    Summary · context
    The demographic and clinical efficacy data were derived from the SURPASS-2 trial.
    Summary · context
    The cost-utility analysis was performed to estimate the cost-utility by UK Prospective Diabetes Study Outcomes Model Version 2.2 from the Chinese health care providers' perspective, incorporating costs and quality-adjusted life years (QALYs).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.